Related Experiment Video
Updated: Jun 9, 2025

11:18
Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
Published on: January 22, 2011
16.0K
The Oncology QCARD Initiative: Fostering efficient evaluation of initial real-world data proposals
Donna R Rivera1, Joy C Eckert2, Carla Rodriguez-Watson2
1Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Pharmacoepidemiology and Drug Safety
|October 28, 2024
Summary
The Oncology QCARD Initiative developed a framework to assess real-world data (RWD) quality for oncology studies. This ensures RWD is fit-for-use and study designs are fit-for-purpose for reliable decision-making.
Area of Science:
- Oncology
- Real-World Data (RWD) Analysis
- Health Informatics
Background:
- The Oncology Quality, Characterization, and Assessment of Real-World Data (QCARD) Initiative addresses the need for robust evaluation of real-world data (RWD) in oncology research.
- Ensuring the quality and suitability of RWD sources is critical for reliable clinical study concepts and decision-making.
Purpose of the Study:
- To develop minimum study design and data elements for evaluating the fitness of RWD sources.
- To facilitate early interaction between study sponsors and scientific reviewers regarding RWD study proposals.
Main Methods:
- A multidisciplinary executive committee guided the initiative.
- A landscape review of literature, guidances, and guidelines was conducted to identify data quality dimensions.
- Expert feedback informed the development of the Oncology QCARD Initial Protocol Characterization (IPC).
Main Results:
- Fit-for-use data (relevant and reliable) and fit-for-purpose design (ensuring validity and transparency) emerged as key themes.
- The QCARD-IPC outlines essential elements for describing RWD study concepts, covering data temporality, populations, exposures, comparators, covariates, endpoints, and quality assurance.
Conclusions:
- Evaluating RWD studies necessitates understanding data sources, design, and potential biases to determine fitness-for-use.
- The Oncology QCARD-IPC offers a structured, transparent approach for preliminary review and improved communication on RWD study proposals.
Related Concept Videos
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Clinical Trials: Overview
2.8K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.8K
Clinical Trials
6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K

